Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CEL-SCI Corporation CVM
$2.48
-$0.21 (-8.49%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
121347915.00000000
-
week52high
5.42
-
week52low
1.86
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.65882300
-
EPS
-0.92000000
-
Last Dividend
0.25000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| EF Hutton | Buy | 25 авг 2022 г. | |
| EF Hutton | Buy | 07 апр 2022 г. | |
| H.C. Wainwright | Buy | 13 янв 2020 г. | |
| Taglich Brothers | Speculative Buy | 20 февр 2013 г. | |
| Chardan Capital | Buy | 13 февр 2013 г. | |
| HC Wainwright & Co. | Buy | 13 янв 2020 г. | |
| EF Hutton | Buy | Buy | 29 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| TALOR EYAL | A | 108177 | 1021 | 30 дек 2022 г. |
| PRICHEP PATRICIA B | A | 213442 | 1825 | 30 дек 2022 г. |
| KERSTEN GEERT R | A | 1152635 | 1851 | 30 дек 2022 г. |
| TALOR EYAL | A | 107156 | 776 | 30 сент 2022 г. |
| ZIMMERMAN DANIEL H | A | 120226 | 1266 | 30 сент 2022 г. |
| PRICHEP PATRICIA B | A | 211617 | 1388 | 30 сент 2022 г. |
| KERSTEN GEERT R | A | 1150784 | 1407 | 30 сент 2022 г. |
| ZIMMERMAN DANIEL H | A | 118960 | 876 | 30 июн 2022 г. |
| TALOR EYAL | A | 106380 | 533 | 30 июн 2022 г. |
| PRICHEP PATRICIA B | A | 210229 | 953 | 30 июн 2022 г. |
Новостная лента
CEL-SCI's Multikine - Potential 21st Century Game-Changing Cancer Drug On The Horizon
Seeking Alpha
30 сент 2022 г. в 11:41
CEL-SCI demonstrated significant clinical benefits for head & neck cancer patients. In the lower-risk group, there was a 14.1% absolute survival improvement.
3 Penny Stocks to Watch With Above Average Volume Today
PennyStocks
18 апр 2022 г. в 15:05
Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.